Youth Extremist Attitudes Driven By Destabilization of Traditional Culture

The paper considers a relevant and burning issue of youth extremism. The authors analyze the reasons for radical and extreme attitudes of the youth and state that extremism among youth is caused by destabilization of the traditional culture. The core of the traditional culture is purposefully destabilized by creating some pseudo-scientific problems and assigning heroic features to minor people in history. Many young people are conscious in their choice of traditionalism with different archaic violence practices which try to openly challenge the modern civility standardized under liberal capitalism and a consumerist society. Mass culture extensively contributes into the development and expansion of the youth extremism patterns. The paper underlines that overall social psychological attitude and confidence of young people in their future, a developed self-consciousness and tradition succession play a huge role in combatting extremism among the youth. Traditional behavioral aspects could oppose extremist manifestations which are rejected at a deep ethnical level of culture, because they contradict its nature and search for development in the today’s world.     Keywords: youth; extremism; traditions; destabilization; culture

Man in ecological globalization

The main idea of this work is define a problem of human ecology, the aim of which to understand outward forms and inward mechanisms of adaptation of social and biological sphere at the different stage of human development. The modern human lost the contacts the nature in a considerable extent. The extent of ecologically personality’s development bounds up with high morals and recreation activities. It forms different needs such as world outlook’s integrity, syncretic of consciousness, freedom of thought and creation, aspiration for realization, for harmony and others in this conditions ecological crisis. Vital activity must be bases upon responsibility’s principle for the future conditions of our planet. The particular importance assumes the process of forming by ecological world outlook at this time, so as the main role at the process of human’s adaptation isconsciousness

THEORETICALLY POSSIBLE AND PRACTICALLY RELIZABLE PRODUCTIVITY OF THE LIGHT-CHESTNUT SOILS OF THE NORTHERN WEST PRECASPIAN REGION ACORDING TO THE MOISTURE AND SOLINITY (ON EXAMPLE OF KOCHUBEY BIOSPHERE STATION OF PIBR DNC RAS)

Abstract. The article presents the productivity data, the species composition and utilization rates phytocenoses FAR depending on theintegrals of dryness and moisture climate volatility, coefficient of moisture and dynamics of harmful salts in the soil according to years and seasons of the year.Methods.The studies were conducted on light-chestnut carbonate saline soil of Kochubey biosphere stations on the territory of the Terek- Kuma Lowland Precaspianregion in 2011–2013. The calculation of the use of FAR was conducted using the formula A.A. Nichiporovich to determine the theoretically possible yield of plants. Klimatogrammy during these years has been compiled by the method Walter. Stocks above and below ground plant matter into account by the method of A.A.Titlyanova.The names of species given by S.K. Cherepanov.Results. According to the results of our observations, the most important for achieving high productivity ephemeral synusia under these conditions include precipitation for April and May. Between the amount of rainfall in April and May and the productivity of abovegroundphytomass ofephemera direct correlation exists, which in 2011 had a strong, and in the next two years-the average severity. In 2012 the volatility increased, KU fell in 5 times. Such weather conditions contributed to the rise of water-soluble salts to the upper soil horizons and substantial change in species composition phytocenoses. The content Cl- in the layer 0–20 cm over the same period 2011 increased in 3.9 times, SO4--- 1.7 in times. If in 2011 the stepen soil salinity in the layer 0–35 cm characterized as weak, in 2012 the average at the same chloride- sulphate type of salinity. Obviously , an increase in the content of Cl- - ions and its relationship to the S04-- contributed to a dramatic increase in productivity and thistle herbs in 2012. Luxuriant growth of Salsola iberica Sennen et Pau particularly stood.Thus, the formation of a biomass and species composition in the Terek-Kuma Lowland Precaspian is the result of the cumulative effects of different environmental factors, the main ones are: precipitation, air temperature, its relative humidity, evaporation, moisture ratio and the degree of soil salinity and chemistry. These dependencies are expressed by the following multiple regression equation. Depending on climatic conditions, the pasture use phytocoenoses 0,20–0,57 % FAR. Win ephemera and ephemeroids of this amount is an average over years of research about 20 %, the remaining 80%-grasses and thistle, the majority of which occur in Salsola iberica Sennen et Pau, bad eating animals and less valuable as fodder representative thistle. Main conclusion.Our results suggest that, in the context of the Terek-Kuma Lowland there are two peaks of productivity of phytocenoses: first one of ephemeras andephemeroids is in mid-May to early July, the second one of grasses and thistleis in the second half of September. The main factors to achieve high productivity ephemeras and ephemeroids on light-chestnut soil of the North- West Precaspian are about 80–85 mm rainfall during April – May, with average daily air temperature 15–16 °C, its relative humidity 70–73 %, volatility of 130–140 mm, KU 0.30, chloride-sulphate type of salinity in the layer of a low degree of 0–35 cm. In years with heavy rainfall in July and August (102 mm), despite an increase in average daily air temperature to 25–26 °C and volatility to 275mm, a relatively high KU (0.21), the content of Cl-in the layer 0–20 cm reduced 1,40 mg-ekv./100 g, ratio Cl-:SO4-- to 0,59–0,84 and productivity grasses and Salsola iberica Sennen et Pauincreased. The FAR utilization reaches 0.57, of which the biomass of grasses and Salsola iberica Sennenet Pau falls 87.6 % (2012).The task of future research is to determine its phitomeliorative role: removal of salt-forming ions from the soil and itsfurther redistribution in ecosystem, considering the nature of movement on the territory of Salsola iberica Sennen et Pau

Ecological Aspects of the Formation of Regraded Solonchak in the Terek-Kuma Lowland of the Caspian

Aim. To reveal the basic patterns and principles of formation on the surface of crusty solonchak of an aeolian-accumulative horizon and its positive transformation at the taxonomic level.Material and Methods. On the surface of crusty solonchak there is formed a layer of silt-sand fractions with seeds of wild phytocenoses which move/перемещаюихся over the surface of the soil under the influence of atmospheric processes with the utilization of woody material protruding above the soil surface to 0.2 m. Analyses, surveys and observations were carried out of the key parts (for investigation - under the aeolian layer) of the crusty solonchak transformed through the dynamics of humidity, lowering of soil moisture (SC), granulometric composition, chemistry and level of soil salinity, as well as determination of the species composition of the phytocenoses and the accumulation of phytomass by plants.Results. The possibility was revealed of a positive transformation within eight years of a layer of silt-sand fractions with seeds of wild phytocenoses in the Wael humus horizon with a capacity of 5 cm ± 0.8 cm and containing 1.26% of humus. The type of salinization remains sulphate-chloride but the level of salinization decreases from very strong in the 0-5 layer to weak one in the 6-15 cm layer - on average. The profile of the crusty solonchak Скк [AJk - AJ,s - BCA,s - Cca,s] is changed to that of regraded solonchak Ckw [Wael - AJ,s - BCA,s - Cca,s]. The granulometric composition of the soil is improved and a productive phytocenosis is formed.Conclusion. The positive transformation of crusty solonchak to regraded contributes to the reduction of soil deflation and of aerial contamination by dust particle fractions, the lowering of carbon emissions from the soil and of the natural greenhouse effect, the increase of the utilization coefficient of photosynthetically active radiation (PAR) and the prevention of excessive overheating of the soil and atmosphere

A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS)

Purpose: Antivascular endothelial growth factor agents are increasingly used in diabetic macular oedema (DME); however, there are few studies exploring their use in DME in real-world settings. Methods: POLARIS was a noninterventional, multicentre study to monitor 12-month outcomes in patients starting ranibizumab treatment in routine practices. The primary outcome was mean change in visual acuity (VA) from baseline to month 12 (last observation carried forward approach). Other outcomes included mean change in central retinal thickness (CRT) and resource utilization. Visual acuity (VA) outcomes were also stratified by country, baseline visual acuity score (VAS), sex, age and injection frequency. Results: Outcomes were analysed from all treated patients (n = 804) and from first-year completers (patients who had a visual acuity assessment at 12 months; n = 568). The mean (SD) baseline VAS was 59.4 (15.9) letters, and the mean change in visual acuity was 4.4 letters (95% confidence interval: 3.3–5.4) at month 12 (study eye; first-year completers). The mean number of injections (study eye) was 4.9, and the mean number of all visits (any eye) was 10 (58% were injection visits) over 12 months (first-year completers). The mean (SD) baseline CRT was 410.6 (128.8) μm, and the mean change in CRT was −115.2 μm at month 12 (study eye; first-year completers). Visual acuity (VA) outcomes were generally comparable across most countries and subgroups and were greatest in patients with the lowest baseline VAS (≤60 letters). Conclusion: POLARIS showed that real-world outcomes in DME patients starting treatment with ranibizumab were lower than those observed in clinical studies, in spite of extensive monitoring. © 2018 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation

Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and Spectri phase 3 randomized clinical trials

IMPORTANCE: Geographic atrophy (GA) secondary to age-related macular degeneration is a leading cause of visual disability in older individuals. A phase 2 trial suggested that lampalizumab, a selective complement factor D inhibitor, reduced the rate of GA enlargement, warranting phase 3 trials.OBJECTIVE: To assess the safety and efficacy of lampalizumab vs sham procedure on enlargement of GA.DESIGN, SETTING, AND PARTICIPANTS: Two identically designed phase 3 double-masked, randomized, sham-controlled clinical trials, Chroma and Spectri, enrolled participants from August 28, 2014, to October 6, 2016, at 275 sites in 23 countries. Participants were aged 50 years or older, with bilateral GA and no prior or active choroidal neovascularization in either eye and GA lesions in the study eye measuring 2.54 to 17.78 mm(2) with diffuse or banded fundus autofluorescence patterns.INTERVENTIONS: Participants were randomized 2:1:2:1 to receive 10 mg of intravitreous lampalizumab every 4 weeks, sham procedure every 4 weeks, 10 mg of lampalizumab every 6 weeks, or sham procedure every 6 weeks, through 96 weeks.MAIN OUTCOMES AND MEASURES: Safety and efficacy assessed as mean change from baseline in GA lesion area at week 48 from centrally read fundus autofluorescence images of the lampalizumab arms vs pooled sham arms, in the intent-to-treat population and by complement factor I-profile genetic biomarker.RESULTS: A total of 906 participants (553 women and 353 men; mean [SD] age, 78.1 [8.1] years) were enrolled in Chroma and 975 participants (578 women and 397 men; mean [SD] age, 77.9 [8.1] years) were enrolled in Spectri; 1733 of the 1881 participants (92.1%) completed the studies through 48 weeks. The adjusted mean increases in GA lesion area from baseline at week 48 were 1.93 to 2.09 mm(2) across all groups in both studies. Differences in adjusted mean change in GA lesion area (lampalizumab minus sham) were -0.02 mm(2) (95% CI, -0.21 to 0.16 mm(2); P = .80) for lampalizumab every 4 weeks in Chroma, 0.16 mm(2) (95% CI, 0.00-0.31 mm(2); P = .048) for lampalizumab every 4 weeks in Spectri, 0.05 mm2 (95% CI, -0.13 to 0.24 mm(2); P = .59) for lampalizumab every 6 weeks in Chroma, and 0.09 mm(2) (95% CI, -0.07 to 0.24 mm(2); P = .27) for lampalizumab every 6 weeks in Spectri. No benefit of lampalizumab was observed across prespecified subgroups, including by complement factor I-profile biomarker. Endophthalmitis occurred after 5 of 12 447 injections (0.04%) or in 5 of 1252 treated participants (0.4%) through week 48.CONCLUSIONS AND RELEVANCE: In Chroma and Spectri, the largest studies of GA conducted to date, lampalizumab did not reduce GA enlargement vs sham during 48 weeks of treatment. Results highlight the substantial and consistent enlargement of GA, at a mean of approximately 2 mm(2) per year

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

Background: To reduce treatment burden and optimise patient outcomes in diabetic macular oedema, we present 1-year results from two phase 3 trials of faricimab, a novel angiopoietin-2 and vascular endothelial growth factor-A bispecific antibody. Methods: YOSEMITE and RHINE were randomised, double-masked, non-inferiority trials across 353 sites worldwide. Adults with vision loss due to centre-involving diabetic macular oedema were randomly assigned (1:1:1) to intravitreal faricimab 6·0 mg every 8 weeks, faricimab 6·0 mg per personalised treatment interval (PTI), or aflibercept 2·0 mg every 8 weeks up to week 100. PTI dosing intervals were extended, maintained, or reduced (every 4 weeks up to every 16 weeks) based on disease activity at active dosing visits. The primary endpoint was mean change in best-corrected visual acuity at 1 year, averaged over weeks 48, 52, and 56. Efficacy analyses included the intention-to-treat population (non-inferiority margin 4 Early Treatment Diabetic Retinopathy Study [ETDRS] letters); safety analyses included patients with at least one dose of study treatment. These trials are registered with ClinicalTrials.gov (YOSEMITE NCT03622580 and RHINE NCT03622593). Findings: 3247 patients were screened for eligibility in YOSEMITE (n=1532) and RHINE (n=1715). After exclusions, 940 patients were enrolled into YOSEMITE between Sept 5, 2018, and Sept 19, 2019, and 951 patients were enrolled into RHINE between Oct 9, 2018, and Sept 20, 2019. These 1891 patients were randomly assigned to faricimab every 8 weeks (YOSEMITE n=315, RHINE n=317), faricimab PTI (n=313, n=319), or aflibercept every 8 weeks (n=312, n=315). Non-inferiority for the primary endpoint was achieved with faricimab every 8 weeks (adjusted mean vs aflibercept every 8 weeks in YOSEMITE 10·7 ETDRS letters [97·52% CI 9·4 to 12·0] vs 10·9 ETDRS letters [9·6 to 12·2], difference −0·2 ETDRS letters [−2·0 to 1·6]; RHINE 11·8 ETDRS letters [10·6 to 13·0] vs 10·3 ETDRS letters [9·1 to 11·4] letters, difference 1·5 ETDRS letters [−0·1 to 3·2]) and faricimab PTI (YOSEMITE 11·6 ETDRS letters [10·3 to 12·9], difference 0·7 ETDRS letters [−1·1 to 2·5]; RHINE 10·8 ETDRS letters [9·6 to 11·9], difference 0·5 ETDRS letters [−1·1 to 2·1]). Incidence of ocular adverse events was comparable between faricimab every 8 weeks (YOSEMITE n=98 [31%], RHINE n=137 [43%]), faricimab PTI (n=106 [34%], n=119 [37%]), and aflibercept every 8 weeks (n=102 [33%], n=113 [36%]). Interpretation: Robust vision gains and anatomical improvements with faricimab were achieved with adjustable dosing up to every 16 weeks, demonstrating the potential for faricimab to extend the durability of treatment for patients with diabetic macular oedema. Funding: F Hoffmann-La Roche